S J S Enterprises Ltd

- No explicit mention of any current or planned fundraising through debt or equity in the transcript. - The company has successfully repaid a term loan of INR 300 crore and currently maintains a net cash balance of INR 388.8 million, indicating a debt-free status. - Focus is on monetizing vacant assets (such as the old Bangalore plant) to strengthen financial conditions which may support organic and inorganic initiatives. - Capital expenditure plans totaling INR 170-190 crore over three years are being funded internally, with specific investments like INR 80 crore for Exotech expansion and INR 40 crore for optical cover glass factory. - No announcements related to raising capital through fresh equity or debt have been made in this earnings call or investor discussion.

- **Exotech Expansion**: Capex of around INR 80 crores planned, with commissioning expected by Q1 FY 2026. This aims to scale production capabilities to meet rising demand. - **Optical Glass Factory**: Investment of INR 40 crores to set up a facility in Hosur, Tamil Nadu, targeting localization near key customers. - **Maintenance Capex**: Approximately INR 15 crores annual maintenance capex for all three companies over the next three years. - **Total Capex Plan**: Around INR 170 to 190 crores over three years, including Exotech expansion, optical glass setup, and maintenance. - **Walter Pack India**: Capacity utilization at 70-75% with 25% spare capacity; earlier heavy capex done. Land parcel acquired for potential future expansion. - **Monetization of Vacant Bangalore Plant**: Board decided to monetize the old vacant plant to strengthen financial conditions and support organic and inorganic initiatives. Expected cash inflow within 12 months but not guaranteed in FY 2025.

- SJS anticipates a revenue growth CAGR of around 14-15% over the next three years, driven by higher sales volumes. - Strong focus on winning global export business, targeting 14-15% of consolidated sales from exports within three years, leveraging new geographical markets like North America, Latin America, Europe, and Southeast Asia. - Significant ramp-ups expected in new global programs won from customers like Stellantis and Visteon, with volumes maturing over 1-3 years. - Expansion in product segments including passenger vehicles, consumer durables, and medical devices, with large growth projected from 4-wheelers and exports. - Organic growth complemented by inorganic opportunities, including acquiring companies in medical devices. - Capacity expansion with new plants (e.g., Exotech plant commissioning in FY 2026 and cover glass plant by FY 2027) supports volume increase. - The company expects to double Exotech revenue in the next three years by improving efficiency and addressing new market pockets.

- Consolidated revenue growth of 18.1% Y-o-Y in Q2 FY2025, driven by passenger vehicle, consumer segments, and exports. - EBITDA margin improved by 370 bps Y-o-Y to 26.6%, with robust operational efficiencies. - PAT grew 50.9% Y-o-Y to INR 291.5 million with a margin of 15.1%. - Expect export revenue to increase to 14%-15% of consolidated sales in the next three years, supported by a strong global OEM order book. - Margins to remain stable around 25%-26% over the long term, with new products and export growth expected to drive profitability. - Capex of INR 170-190 crores planned over three years, including INR 80 crores for Exotech expansion starting FY2025, which will support revenue scaling. - EBITDA margins for subsidiaries like Walter Pack expected to improve as sales ramp up. - Overall outlook: sustained revenue and profitability growth driven by exports, capacity expansions, and product innovation.

- SJS Enterprises has a strong order intake, including new prestigious models from customers like Bajaj, TVS, Royal Enfield, Mahindra, and HMSI. - The company is winning significant new business in both domestic and export markets, notably a large long-term export order from a global OEM covering North America, Latin America, and Europe. - Export business is growing rapidly, aiming for 14-15% of total sales over the next three years. - A new plant (Exotech) is expected to start operations in FY 2026 Q1, targeting to double revenue in 3 years. - Management expects steady ramp-up of new global business orders, which take 1-2 years to mature to full volume. - The company is actively pursuing inorganic growth opportunities, including in medical devices and asset monetization to support business expansion. - Overall, the order book reflects a mix of ongoing strong domestic demand and expanding global export opportunities.